Literature DB >> 14969051

Biochemical markers of joint tissue turnover in early rheumatoid arthritis.

P Garnero1, P Geusens, R Landewé.   

Abstract

The progression of rheumatoid arthritis (RA), a disease characterized by synovitis, cartilage degradation and bone erosion, is highly variable from patient to patient. New specific biological markers reflecting quantitative and dynamic changes in joint tissue turnover have been recently developed and include assays for type II collagen synthesis and degradation and synovitis. Increasing evidence from prospective studies in early RA indicate that some of these markers may be useful to predict the progression and identify patients at risk for rapid joint damage, before any damage is detected by radiography. Although studies on their value in assessing the efficacy of treatments are still limited, preliminary data in early RA suggest that biological markers will play an important role in the development and the early monitoring of disease modifying antirheumatic drugs with respect to future radiographic progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14969051

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  The efficacy of shikonin on cartilage protection in a mouse model of rheumatoid arthritis.

Authors:  Young Ock Kim; Seung Jae Hong; Sung-Vin Yim
Journal:  Korean J Physiol Pharmacol       Date:  2010-08-31       Impact factor: 2.016

3.  Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.

Authors:  Arno W R van Kuijk; Jeroen DeGroot; Rishma C Koeman; Nico Sakkee; Dominique L Baeten; Danielle M Gerlag; Paul P Tak
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

Review 4.  Understanding emerging treatment paradigms in rheumatoid arthritis.

Authors:  Ferdinand C Breedveld; Bernard Combe
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

5.  Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.

Authors:  S M M Verstappen; A R Poole; M Ionescu; L E King; M Abrahamowicz; D M Hofman; J W J Bijlsma; F P J G Lafeber
Journal:  Arthritis Res Ther       Date:  2006-01-10       Impact factor: 5.156

6.  Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Authors:  Anita Boyapati; Jérôme Msihid; Stefano Fiore; Janet van Adelsberg; Neil M H Graham; Jennifer D Hamilton
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

7.  Comparison of hyaluronic acid in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.

Authors:  Bogdan Cylwik; Ewa Gruszewska; Ewa Gindzienska-Sieskiewicz; Otylia Kowal-Bielecka; Lech Chrostek
Journal:  Biochem Med (Zagreb)       Date:  2021-04-15       Impact factor: 2.313

Review 8.  Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.

Authors:  Paul Emery; Cem Gabay; Maarten Kraan; Juan Gomez-Reino
Journal:  Rheumatol Int       Date:  2007-05-16       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.